The offering buys minimal time (into Q4 2026) against a backdrop of Nasdaq delisting risk, negative working capital, and a going-concern warning. The concurrent warrants create massive overhang that will only clear if stockholder approval is obtained. Monitor the Nasdaq hearing outcome in late August 2026 — a delisting would be catastrophic for liquidity and further capital raising. The stock is likely to trade under pressure from the dilutive overhang and near-term cash runway concerns.
Price Chart
Executive Summary
Dare Bioscience priced a ~$6.0M public offering of 4,085,687 shares of common stock and 293,894 pre-funded warrants at $1.37/share, alongside a concurrent private placement of warrants for up to 8,759,162 additional shares. The offering comes just 4 days after the company reported Q2 results showing a net loss of -$0.20/share (beating consensus of -$0.33) but with cash dropping to $12.6M, negative working capital, and an active Nasdaq delisting risk with a hearing scheduled for late August 2026. The net proceeds of ~$5.4M extend the cash runway only into Q4 2026, and the massive potential dilution from the concurrent warrants (requiring stockholder approval to become exercisable) creates significant overhang.
Key Facts
- Offering of 4,085,687 shares + 293,894 pre-funded warrants at $1.37/share for ~$6.0M gross proceeds (~$5.4M net)
- Concurrent private placement of Series A and B warrants to purchase up to 8,759,162 additional shares at $1.37, exercisable only if stockholder approval is obtained
- Company has $12.6M cash (all grant funds), negative working capital of ~$0.2M, and accumulated deficit of ~$194.7M as of June 30, 2026
- Nasdaq delisting hearing scheduled for late August 2026 due to stockholders' equity < $2.5M; company is under a mandatory monitoring period
- Existing cash expected to fund operations only into Q4 2026; substantial doubt about going concern raised explicitly
- Immediate dilution of $1.12/share for new investors; pro forma net tangible book value of $0.25/share vs. offering price of $1.37
- Q2 2026 net loss of -$0.20/share beat consensus of -$0.33 but cash burn continues at ~$12.3M operating cash outflow in H1 2026
Financial Impact
~$5.4M net proceeds raised, extending cash runway only into Q4 2026; immediate dilution of $1.12/share (82% of offering price); potential future dilution from up to 8.76M additional shares via concurrent warrants
Risk Factors
- Nasdaq delisting determination hearing in late August 2026 — unfavorable outcome would suspend trading and impair capital access
- Cash runway only into Q4 2026; substantial doubt about going concern; will need additional dilutive financing soon
- Concurrent warrants for up to 8.76M shares create massive overhang; exercisability depends on stockholder approval which is uncertain
- Immediate 82% dilution for new investors; further dilution from existing options/warrants/convertible preferred
- No minimum offering requirement means actual proceeds could be less than $5.4M if not all shares sold
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-038646 |
| Document: 0001493152-26-038646-index-headers.html | 0001493152-26-038646 |
| Document: 0001493152-26-038646-index.html | 0001493152-26-038646 |
| Document: 0001493152-26-038646.txt | 0001493152-26-038646 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | DEF 14A | $0.7900 $0.7720 | ▲ +2.28% | ▲ +1.86% | $0.6467 (+18.14%) |
Oct 1, 2026 25d ago | 8-K | $0.8510 $0.8428 | ▼ −0.96% | ▼ −1.70% | $0.6467 (−24.01%) |
Sep 9, 2026 6w ago | 8-K | $0.7166 $0.7051 | ▼ −1.60% | ▼ −1.01% | $0.6467 (−9.75%) |
Sep 4, 2026 7w ago | EFFECT | $0.7210 $0.7130 | ▲ +1.11% | ▲ +0.56% | $0.6467 (+10.31%) |
Aug 17, 2026 10w ago | 8-K | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 17, 2026 10w ago | 424B5 | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 13, 2026 10w ago | 8-K | $0.9300 $0.8102 | ▼ −12.88% | ▼ −12.41% | $0.6467 (−30.46%) |
Aug 6, 2026 11w ago | Press Release | $1.33 $1.40 | ▲ +5.26% | ▲ +4.65% | $0.6467 (−51.38%) |
Jul 24, 2026 13w ago | 8-K | $1.28 $1.32 | ▲ +3.13% | ▲ +3.10% | $0.6467 (−49.48%) |
Jul 13, 2026 15w ago | 8-K | $2.09 $2.07 | ▼ −0.96% | ▼ −1.31% | $0.6467 (−69.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers